Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study

Patients with locally advanced basal cell carcinoma (laBCC) or metastatic BCC (mBCC), two difficult‐to‐treat populations, have had limited treatment options. Sonidegib, a hedgehog pathway inhibitor (HPI), was approved in laBCC based on results from the BOLT trial.

[1]  A. Pereira,et al.  Targeting the Hedgehog Pathway in Cancer: Current Evidence and Future Perspectives , 2019, Cells.

[2]  C. Swanton,et al.  Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  C. Verschraegen,et al.  Metastatic Solid Tumors , 2019 .

[4]  A. Hauschild,et al.  Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study , 2017, BMC Cancer.

[5]  E. Hurh,et al.  Exposure‐Response Analysis of Sonidegib (LDE225), an Oral Inhibitor of the Hedgehog Signaling Pathway, for Effectiveness and Safety in Patients With Advanced Solid Tumors , 2016, Journal of clinical pharmacology.

[6]  R. Dummer,et al.  The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. , 2016, Journal of the American Academy of Dermatology.

[7]  J. Nedelman,et al.  Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors , 2016, Cancer Chemotherapy and Pharmacology.

[8]  R. Dummer,et al.  Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. , 2015, The Lancet. Oncology.

[9]  A. Hauschild,et al.  Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. , 2015, Journal of the American Academy of Dermatology.

[10]  A. Hauschild,et al.  Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. , 2015, The Lancet. Oncology.

[11]  M. Hidalgo,et al.  Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.

[12]  A. El-Khoueiry,et al.  A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.

[13]  A. Wysong,et al.  An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. , 2014, Journal of the American Academy of Dermatology.

[14]  P. Dziewulski,et al.  Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective , 2014, British Journal of Cancer.

[15]  Christopher J. Miller,et al.  Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update (30-month) of the pivotal ERIVANCE BCC study. , 2014 .

[16]  R. Dummer,et al.  A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.

[17]  Anna Tostevin,et al.  An observational multi-cohort study on the use and safety of Combivir scored tablets among HIV-infected children and adolescents. Report to the European Medicines Agency (EMA)/ Committee for Medicinal Products for Human Use (CHMP) , 2014 .

[18]  J. Hainsworth,et al.  Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. , 2014, Journal of the American Academy of Dermatology.

[19]  J. Blay,et al.  GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  A. Colevas,et al.  Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma , 2013, The British journal of dermatology.

[21]  M. Prados,et al.  A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): A Pediatric Brain Tumor Consortium study (PBTC 25B). , 2013 .

[22]  C. Rudin,et al.  Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors , 2013, Clinical Cancer Research.

[23]  Kris Chang,et al.  Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. , 2012, The New England journal of medicine.

[24]  Aleksandar Sekulic,et al.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma. , 2012, The New England journal of medicine.

[25]  J. Berlin,et al.  Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors , 2011, Clinical Cancer Research.

[26]  C. Rudin,et al.  Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors , 2011, Clinical Cancer Research.

[27]  A. Abernethy,et al.  PCN122 DEVELOPMENT OF THE PATIENT-REPORTED VERSION OF THE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (PRO-CTCAE) , 2010 .

[28]  Lixin Lang,et al.  A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. , 2010 .

[29]  P. LoRusso,et al.  Review: Targeting the Hedgehog pathway in cancer , 2010, Therapeutic advances in medical oncology.

[30]  M. Warmuth,et al.  Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist. , 2010, ACS medicinal chemistry letters.

[31]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[32]  COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ( CHMP ) GUIDELINE ON CONDUCT OF PHARMACOVIGILANCE FOR MEDICINES USED BY THE PAEDIATRIC POPULATION , 2007 .

[33]  Lee L. Rubin,et al.  Targeting the Hedgehog pathway in cancer , 2006, Nature Reviews Drug Discovery.

[34]  M. Wolter,et al.  Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas , 2005, The British journal of dermatology.

[35]  D. Kuijpers,et al.  Basal Cell Carcinoma , 2002, American journal of clinical dermatology.

[36]  H. W. Randle.  Basal and Squamous Cell Skin Cancers of the Head and Neck , 1996 .

[37]  T. Taguchi,et al.  [Phase I study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[38]  B. Chevallier,et al.  [Metastatic basal cell carcinoma]. , 1993, Annales de dermatologie et de venereologie.

[39]  B. Guyuron,et al.  Long-term survival following nodal metastases from basal cell carcinoma. , 1990, Annals of plastic surgery.

[40]  S. Frankel,et al.  Non-melanoma Skin Cancer , 2021, Surgical Oncology Manual.

[41]  H. von Domarus,et al.  Metastatic basal cell carcinoma , 1984 .

[42]  F. Cramer.  Somatic mutations , 1978, Nature.